We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01618656
Recruitment Status : Active, not recruiting
First Posted : June 13, 2012
Last Update Posted : November 30, 2017
Information provided by (Responsible Party):

June 5, 2012
June 13, 2012
November 30, 2017
June 2012
December 2018   (Final data collection date for primary outcome measure)
  • Marijuana Withdrawal Checklist [ Time Frame: Completed each time subject seen over approximately 16 weeks ]
    32-item checklist evaluating potential symptoms of cannabis withdrawal
  • Self reported cannabis use [ Time Frame: Evaluated each time subject seen over approximately 16 weeks ]
    Subject quantifies and reports frequency of cannabis use prior to study participation and during
  • THC-COOH Quantification [ Time Frame: 12 times over approximately 16 weeks ]
    Subjects provide urine samples to quantify levels of THC
  • Marijuana Craving Scale [ Time Frame: 15 times over approximately 16 weeks ]
    Scale to assess severity of craving for marijuana
  • Relapse Rates [ Time Frame: After one week of abstinence ]
    Subjects will frequently be evaluated to determine if they are able to maintain abstinence after one week of study treatment, at the end of the treatment period as well as at the end of the non-treatment follow up period.
Same as current
Complete list of historical versions of study NCT01618656 on ClinicalTrials.gov Archive Site
  • Polysomnography [ Time Frame: Two nights prior to study treatment, three nights during study treatment and two nights at the end of study treatment (four weeks later) ]
    Measurement of sleeping patterns
  • Cognitive Testing [ Time Frame: Once pre-treatment, twice during treatment (within 4 weeks) and once during the non-treatment follow up (within 8 weeks) ]
    Various computerized tests of memory, attention and learning
Same as current
Not Provided
Not Provided
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
FAAH-Inhibitor for Cannabis Dependence
Cannabis dependence is associated with changes in the brain's cannabinoid system. When cannabis dependent individuals try to quit using cannabis, some of them experience problems that make it difficult for them to achieve and maintain abstinence. Therefore, reducing the problems related to quitting cannabis may facilitate abstinence. One way to do this is by harnessing the brain's capacity to make its own cannabis-like substances - endocannabinoids. One of the main endocannabinoids is anandamide. The study is based on the hypothesis that the problems related to quitting cannabis use will be reduced by increasing the brain levels of anandamide. Furthermore, by reducing the problems related to quitting cannabis, people will be less likely to relapse. Brain anandamide levels will be increased by blocking the breakdown of anandamide using a fatty acid amide hydrolase inhibitor (FAAH-I). The effects of a novel FAAH-I cannabis withdrawal and relapse in cannabis dependent subjects will be studied in a double-blind, randomized, controlled, proof-of-concept study. Cannabis-dependent subjects will receive placebo or the FAAH-inhibitor PF-04457845 in a 2:1 randomization. The trial consists of a 1 week inpatient stay to achieve abstinence, a 3 week outpatient treatment phase and a 8 week follow-up phase. Abstinence and relapse will be measured at various times during this 12 week study.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cannabis Dependence
  • Drug: PF-04457845
    Study medication will be administered at 4mg by mouth daily for four weeks.
  • Drug: Placebo
    Sugar pill
  • Active Comparator: PF-04457845
    2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
    Intervention: Drug: PF-04457845
  • Placebo Comparator: Placebo (sugar pill)
    1/3 of subjects will be randomized to placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 2018
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male
  2. Ages 18-55 (inclusive)
  3. Cannabis Dependence

Exclusion Criteria:

  1. Allergies or intolerance to FAAH-Inhibitors
  2. Current significant medical or other comorbidities
Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
U01DA033267 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Deepak C. D'Souza, Yale University
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Deepak C D'Souza, MD Yale University
Yale University
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP